(Q37834646)

24 August 2017

1 reference

title

Laboratory assessment of new anticoagulants (English)

1 reference

24 August 2017

1 reference

1 reference

0 references

Meyer M Samama

1

1 reference

24 August 2017

Céline Guinet

series ordinal

2

1 reference

24 August 2017

publication date

3 February 2011

1 reference

Clinical Chemistry and Laboratory Medicine

24 August 2017

published in

1 reference

24 August 2017

volume

49

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

761-772

1 reference

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Newer anticoagulants in 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery--TREK: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

New oral anticoagulants in development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Monitoring the new antithrombotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Cofactor proteins in the assembly and expression of blood clotting enzyme complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Thrombin generation testing in routine clinical practice: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

No functional role of plasminogen activator inhibitor-1 in murine adipogenesis or adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Anticoagulation by factor Xa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

The ecarin clotting time, a universal method to quantify direct thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Monitoring of anticoagulant effects of direct thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Hirudin determination in plasma can be strongly influenced by the prothrombin level

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Rap1b is critical for glycoprotein VI-mediated but not ADP receptor-mediated alpha2beta1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

Monitoring Thrombin Generation by Electrochemistry: Development of an Amperometric Biosensor Screening Test for Plasma and Whole Blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

The pharmacokinetics of fondaparinux sodium in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.134

21 January 2018

Identifiers

DOI

10.1515/CCLM.2011.134

1 reference

24 August 2017

1 reference